Sterling Capital Management’s Janux Therapeutics JANX Stock Holding History

Sterling Capital Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4K	Sell	871 -180	-17%	-$2.61K	﹤0.01%	2077
2026 Q1	$14.6K	Sell	1,051 -712	-40%	-$9.76K	﹤0.01%	2175
2025 Q4	$24.3K	Sell	1,763 -110	-6%	-$2.59K	﹤0.01%	2121
2025 Q3	$45.8K	Buy	1,873 +1,121	+149%	+$27.3K	﹤0.01%	1784
2025 Q2	$17.4K	Buy	752 +717	+2,049%	+$18.9K	﹤0.01%	1844
2025 Q1	$945	Buy	35 +6	+21%	+$226	﹤0.01%	2837
2024 Q4	$1.55K	Hold	29	–	–	﹤0.01%	2846
2024 Q3	$1.32K	Buy	+29	New	+$1.26K	﹤0.01%	2392

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Sterling Capital Management's JANX Position: Q2 2026 in Review

Sterling Capital Management reduced its Janux Therapeutics (JANX) stake by 17% in Q2 2026, selling an estimated $2.61K and leaving 871 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Sterling Capital Management first reported a position in JANX in Q3 2024 and has held it in 8 quarters since. The position peaked at $45.8K in Q3 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Sterling Capital Management held 871 shares of Janux Therapeutics worth $13.4K as of Q2 2026.
Sterling Capital Management sold 180 Janux Therapeutics shares in Q2 2026, an estimated $2.61K.
Janux Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2077 holding.
Sterling Capital Management first reported a position in Janux Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Janux Therapeutics position peaked at $45.8K in Q3 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.